|
|
Volumn 90, Issue 20, 1998, Pages 1514-1528
|
|
Cancer chemoprevention: Progress and promise - Commentary
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
(4' PYRROLIDINOETHOXYPHENYL)PHENYL 6 HYDROXY 1,2,3,4 TETRAHYDRONAPTHALENE DEXTRO TARTRATE;
1,2,3,4,9,9A HEXAHYDRO 2 [2 (2 METHOXYPHENYL) 1 OXO 2 PROPENYL] 9 (4 METHYLPHENYL) 4,9 ETHANO 3AH BENZ[F]ISOINDOLE 3A CARBOXYLIC ACID;
2 (3 CHLOROANILINO) 4 [2 (3 HYDROXYPROPYLAMINO) 4 PYRIDYL]PYRIMIDINE;
2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER;
4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE;
4 [1 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CYCLOPROPYL]BENZOIC ACID;
4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE;
4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE;
5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE;
6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID;
6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID;
ACETYLSALICYLIC ACID;
ALPHA (3,5 DICHLOROBENZYLIDENE) 3 PYRIDYLACETONITRILE;
ALPHA TOCOPHEROL;
ANGIOGENESIS INHIBITOR;
AROMATASE INHIBITOR;
ARZOXIFENE;
ASCORBIC ACID;
BETA CAROTENE;
BEXAROTENE;
BMS 453;
BMS 753;
BMS 961;
CD 2314;
CD 666;
CEP 1347;
CEP 751;
CGP 59326;
CGP 77876;
CYCLIN DEPENDENT KINASE INHIBITOR;
DUTASTERIDE;
EB 1231;
EGF 771;
ENZYME INHIBITOR;
ESTROGEN RECEPTOR;
FENRETINIDE;
FINASTERIDE;
FLOSULIDE;
FULVESTRANT;
ILX 23 7553;
IMATINIB;
LEFLUNOMIDE;
LEXACALCITOL;
LGD 1550;
LONAFARNIB;
LY 320236;
MATRIX METALLOPROTEINASE INHIBITOR;
MC 1627;
MINERAL;
MMI 270;
MOLYBDENUM;
MULTIVITAMIN;
N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE;
NONSTEROID ANTIINFLAMMATORY AGENT;
PD 146568;
PD 169451;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;
PRINOMASTAT;
PROSTAGLANDIN SYNTHASE INHIBITOR;
PROTEIN FARNESYLTRANSFERASE INHIBITOR;
PROTEIN TYROSINE KINASE INHIBITOR;
RALOXIFENE;
RETINOID;
RETINOL;
RIBOFLAVIN;
RO 24 5531;
ROFECOXIB;
RWJ 57504;
SAM 486A;
SELENIUM;
SEMAXANIB;
SEOCALCITOL;
SR 11238;
STEROID 5ALPHA REDUCTASE INHIBITOR;
TAMIBAROTENE;
TAMOXIFEN;
TANOMASTAT;
TIPIFARNIB;
TP 69;
TP 72;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VATALANIB;
VITAMIN D DERIVATIVE;
ZINC;
BREAST CANCER;
CANCER INCIDENCE;
CANCER RISK;
CARCINOGENESIS;
CHEMOPROPHYLAXIS;
CLINICAL TRIAL;
DIET;
DISEASE ASSOCIATION;
ENDOMETRIUM CANCER;
FRACTURE;
HUMAN;
INFECTION;
LUNG CANCER;
MALIGNANT NEOPLASTIC DISEASE;
MENOPAUSE;
NONHUMAN;
NOTE;
ORAL DRUG ADMINISTRATION;
PRIORITY JOURNAL;
PROSTATE CANCER;
RISK BENEFIT ANALYSIS;
SKIN CANCER;
THROMBOSIS;
|
|
EID: 0032556186
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/90.20.1514 Document Type: Note |
|
Times cited : (145)
|
|
References (114)
|
